CDK1 and neuroblastoma: Used at low concentrations, Dinaciclib is a broad CDK inhibitor (CDK1, 2, 5, and 9), but its antagonistic effect on CDK2 and CDK9 has been attributed to its ability to suppress neuroblastoma cell proliferation (31).